Navigation Links
Leuven research opens new pathway for the treatment of Alzheimer's disease
Date:12/4/2012

Scientists from VIB and KU Leuven have discovered a new target molecule for the development of a treatment against Alzheimer's disease. There is currently no cure for this disease. Many candidate drugs fail because they also target proteins essential to life. This discovery from Leuven could form a target for a treatment against Alzheimer's disease with fewer side effects and that suppresses the very first symptoms of the disease. This research will be published in the leading journal Nature Medicine.

Alzheimer's Disease

Alzheimer's Disease is the most common form of dementia in the West. The damage to memory and mental function causes one of the most terrifying clinical pictures. The current drugs for Alzheimer patients support memory for a short time, but they do not stop the death of brain cells. Recent insights have shown that Alzheimer's disease causes biochemical changes in the brain many years before the symptoms of dementia are present. It is very important to develop drugs that can be taken at this early stage in order to prevent the disease.

The ɣ-secretase complex

Many candidate drugs have an effect on the ɣ-secretase complex. This complex cuts proteins at specific sites and plays an important role in the development of amyloid plaques, a pathological hallmark in of the brains of Alzheimer patients. Aberrant and excessive cleavage of the amyloid precursor protein by the y-secretase complex results in the accumulation and deposition of the β-amyloid protein in amyloid plaques.

However, the ɣ-secretase complex is also involved in cleavage of a series of other proteins essential to life. As a result, many candidate drugs that act on the ɣ-secretase complex produce toxic side effects.

GPCRs and β-arrestin

GPCRs are a family of proteins that serve as the targets of the majority of all currently marketed drugs. The Nobel Prize in Chemistry for 2012 was awarded to Dr. Robert Lefkowitz and Dr. Brian Kobilka for their groundbreaking work in this field and the many medical applications of this knowledge. It is known that GPCRs also play a role in the development of Alzheimer's disease, but it is not yet clear how GPCRs regulate the ɣ-secretase complex.

β-arrestins are a family of proteins that classically block or limit GPCR activation; however, it has been recently appreciated that β-arrestins also have additional functions. Therefore, Amantha Thathiah set up a study under the supervision of Bart De Strooper to examine the involvement of β-arrestins in the development of Alzheimer's disease.

The scientists succeeded for the first time in demonstrating that β-arrestin 2 plays a role in regulation of the ɣ-secretase complex function and in the development of Alzheimer's disease in an Alzheimer's disease mouse model. More specifically, β-arrestin 2 interacts with two GPCRs that are known to play a role in the development of Alzheimer's disease. Moreover, expression of β-arrestin 2 is also elevated in individuals with Alzheimer's disease.

Impact of the research

This research opens a new pathway for the treatment of Alzheimer's disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. Therefore, this study provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer's disease.


'/>"/>
Contact: Evy Vierstraete
evy.vierstraete@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their new high-speed ... Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS Expo on ... diode standard packages feature a TO-46 metal can with active areas of 1.0mm and ...
(Date:2/10/2016)... ... 10, 2016 , ... PatientCrossroads announces that the ... online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals since ... which seeks to advance understanding of the hereditary risks for certain kinds of ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... and current winner of the Highest Overall Customer Rating Award from Circuits ... of its business units across the USA, Canada, Mexico and China. , The ...
Breaking Biology Technology:
(Date:1/27/2016)... Ohio , Jan. 27, 2016  Rite Track, ... based in West Chester, Ohio ... award winning service staff, based in Austin, ... capacity and ability to provide modifications, installations and technical ... Dovalina , CEO of PLUS, commented, "PLUS has provided ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
Breaking Biology News(10 mins):